JAMA Clinical Reviews
JAMA Editors’ Choice 2024: Clinical Reviews Podcasts
Jan 2, 2025
Robert Kushner, a renowned author and professor at Northwestern University's Feinberg School of Medicine, dives into the latest advancements in obesity treatment. He discusses new FDA-approved medications, such as semaglutide and terzepatide, highlighting their effectiveness and side effects. Kushner emphasizes the importance of treating obesity as a chronic disease, the potential implications of stopping medication, and the need for gradual dose adjustments. This insightful conversation sheds light on the evolving landscape of obesity management.
22:04
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- The podcast emphasizes the efficacy of FDA-approved anti-obesity medications, highlighting their potential for significant weight loss and manageable side effects.
- There is a critical discussion on dialysis options for chronic kidney failure, underscoring the importance of patient choice and lifestyle management in treatment decisions.
Deep dives
Effectiveness of Anti-Obesity Medications
Three FDA-approved anti-obesity medications—liraglutide, semaglutide, and terzepatide—are effective in addressing obesity, affecting approximately 19% of women and 14% of men globally. Semaglutide, for instance, can result in an average weight loss of about 15%, while terzepatide may achieve 20% weight loss compared to placebo. While these medications mitigate appetite dysregulation, side effects primarily involve gastrointestinal issues, which can be managed through gradual dosage increases and dietary modifications. Counseling on a healthy diet, such as choosing smaller meals and reducing fat intake, further minimizes these side effects and supports successful weight management efforts.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
